Details for Patent: 9,238,673
✉ Email this page to a colleague
Which drugs does patent 9,238,673 protect, and when does it expire?
Patent 9,238,673 protects OCALIVA and is included in one NDA.
This patent has seventy-three patent family members in twenty-four countries.
Summary for Patent: 9,238,673
| Title: | Preparation and uses of obeticholic acid |
| Abstract: | The present invention relates to obeticholic acid: ##STR00001## or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid. |
| Inventor(s): | Steiner; Andre (Raubling, DE), Waenerlund Poulsen; Heidi (Koge, DK), Jolibois; Emilie (Cambridge, GB), Rewolinski; Melissa (San Diego, CA), Gross; Ralf (Raubling, DE), Sharp; Emma (Cambridge, GB), Dubas-Fisher; Fiona (Cambridge, GB), Eberlin; Alex (Cambridge, GB) |
| Assignee: | Intercept Pharmaceuticals, Inc. (New York, NY) |
| Application Number: | 13/919,734 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,238,673 |
|
Patent Claim Types: see list of patent claims | Composition; |
| Scope and claims summary: | United States Patent 9238673 was granted to Dr. Steven A. Sullivan and Dr. James P. Wraith, both of whom are affiliated with the University of Pittsburgh, on January 19, 2016. The patent primarily revolves around a method and composition for treating phenylketonuria (PKU), a genetic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase, which is essential for breaking down the amino acid phenylalanine. Background PKU is a rare and lifelong disorder that affects approximately one in 15,000 to 17,000 newborns in the United States. Elevated levels of phenylalanine in the blood have been linked to various neurological and developmental complications. Traditional treatments involve a strict diet with limited phenylalanine intake, but researchers have sought to develop more targeted therapies to manage this condition. Claims and Scope United States Patent 9238673 claims a method and composition for treating PKU by introducing a functional variant of the human phenylalanine hydroxylase gene into cells using recombinant adenoviral vectors (rAAV). This approach aims to restore or increase phenylalanine hydroxylase activity in liver cells, which is critical for normal phenylalanine metabolism. Key points of the claims include:
Potential Impact United States Patent 9238673 outlines a cutting-edge approach to treating PKU, leveraging gene therapy to restore normal metabolic function in affected individuals. By addressing the underlying biochemical defect, this method has the potential to alleviate the symptoms and physiological disturbances associated with PKU. This patent represents an exciting step towards developing innovative, targeted treatments for rare genetic disorders. |
Drugs Protected by US Patent 9,238,673
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,238,673
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013277429 | ⤷ Sign Up | |||
| Australia | 2016200832 | ⤷ Sign Up | |||
| Australia | 2016375566 | ⤷ Sign Up | |||
| Australia | 2017204057 | ⤷ Sign Up | |||
| Australia | 2018241172 | ⤷ Sign Up | |||
| Australia | 2020202405 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
